Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up

Written by Sharon Salt, Editor
Epilepsy and seizure Movement disorders Neurodegeneration and degenerative disease News Reports

This week, we’re covering some of the latest industry headlines on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s disease and cannabidiol oral solution for seizures. Discover more about our selection of this week’s highlights below: Cannabinoid-derived drug (Epidyolex™) gains positive CHMP opinion for seizures Ponesimod hits key endpoints for Phase III trial in adults with relapsing multiple sclerosis Accordion Pill® fails to achieve statistical superiority to Sinemet® for Parkinson’s disease Cannabinoid-derived drug (Epidyolex™) gains positive CHMP opinion for seizures GW Pharmaceuticals (CA, USA) has received a positive opinion for Epidyolex™ (cannabidiol) for its use as an adjunctive...

To view this content, please register now for access

It's completely free